Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis
Yasaman Vali, Jenny Lee, Jérôme Boursier, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 2, pp. 252-262
Open Access | Times Cited: 212

Showing 1-25 of 212 citing articles:

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Annalisa Berzigotti, Emmanuel Tsochatzis, Jérôme Boursier, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 3, pp. 659-689
Open Access | Times Cited: 1144
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 651
Advancing the global public health agenda for NAFLD: a consensus statement
Jeffrey V. Lazarus, Henry E. Mark, Quentin M. Anstee, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 19, Iss. 1, pp. 60-78
Open Access | Times Cited: 527
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
P. Barton Duell, Francine K. Welty, Michael Miller, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2022) Vol. 42, Iss. 6
Open Access | Times Cited: 383
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Scott L. Friedman, Massimo Pinzani
Hepatology (2021) Vol. 75, Iss. 2, pp. 473-488
Open Access | Times Cited: 284
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
Wah‐Kheong Chan, Kee Huat Chuah, Ruveena Bhavani Rajaram, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 3, pp. 197-213
Open Access | Times Cited: 265
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis
Emmanuel Selvaraj, Ferenc E. Mózes, Arjun Jayaswal, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 4, pp. 770-785
Open Access | Times Cited: 235
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong‐Ju Yoo, et al.
Clinical and Molecular Hepatology (2021) Vol. 27, Iss. 3, pp. 363-401
Open Access | Times Cited: 222
Non-alcoholic fatty liver disease: A patient guideline
Sven Francque, Giulio Marchesini, Achim Kautz, et al.
JHEP Reports (2021) Vol. 3, Iss. 5, pp. 100322-100322
Open Access | Times Cited: 207
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases
Pere Ginés, Laurent Castéra, Frank Lammert, et al.
Hepatology (2021) Vol. 75, Iss. 1, pp. 219-228
Open Access | Times Cited: 187
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
Michelle T. Long, Mazen Noureddin, Joseph K. Lim
Gastroenterology (2022) Vol. 163, Iss. 3, pp. 764-774.e1
Open Access | Times Cited: 182
Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
Leen Heyens, Dana Busschots, Ger H. Koek, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 162
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. s49-s67.2
Open Access | Times Cited: 149
Impact of non-invasive biomarkers on hepatology practice: Past, present and future
Quentin M. Anstee, Laurent Castéra, Rohit Loomba
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1362-1378
Open Access | Times Cited: 148
Current therapies and new developments in NASH
Jean‐François Dufour, Quentin M. Anstee, Elisabetta Bugianesi, et al.
Gut (2022) Vol. 71, Iss. 10, pp. 2123-2134
Open Access | Times Cited: 147
Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events
Jérôme Boursier, Hannes Hagström, Mattias Ekstedt, et al.
Journal of Hepatology (2022) Vol. 76, Iss. 5, pp. 1013-1020
Open Access | Times Cited: 130
Defining comprehensive models of care for NAFLD
Jeffrey V. Lazarus, Quentin M. Anstee, Hannes Hagström, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 10, pp. 717-729
Closed Access | Times Cited: 107
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study
Yasaman Vali, Jenny Lee, Jérôme Boursier, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 8, pp. 714-725
Open Access | Times Cited: 94
Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants
Veeral Ajmera, Beom Kyung Kim, Kun Yang, et al.
Gastroenterology (2022) Vol. 163, Iss. 4, pp. 1079-1089.e5
Open Access | Times Cited: 90
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 797-809
Closed Access | Times Cited: 86
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Monica A. Tincopa, Rohit Loomba
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 7, pp. 660-670
Closed Access | Times Cited: 84
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH
Nikolai V. Naoumov, Dominique Brees, Juergen Loeffler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 5, pp. 1399-1409
Closed Access | Times Cited: 77
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 74
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Arun J. Sanyal, Lee M. Kaplan, Juan P. Frías, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2037-2048
Open Access | Times Cited: 53
Non-invasive testing and risk-stratification in patients with MASLD
Mirko Zoncapè, Antonio Liguori, Emmanuel Tsochatzis
European Journal of Internal Medicine (2024) Vol. 122, pp. 11-19
Closed Access | Times Cited: 36
Page 1 - Next Page

Scroll to top